Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
| The Manila Times
Presentations feature mechanistic data on ACR-2316, a potential first-in-class, clinical WEE1/PKMYT1 inhibitor, rationally designed with AP3 for potent single agent activity and superior therapeutic index